Reconstitute with 20mM Tris and 150mM NaCl to 0.1-1.0mg/ml. Do not vortex. Lyophilized from 20mM Tris, 150mM NaCl, 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose, ProClin 300.
Expression System:
E. coli
Formulierung:
Lyophilized powder
Sequenz:
N-terminal His-Tag, Ser41~Ser209 (NP_003811.2)
Anwendungsbeschreibung:
TNFRSF14 (Tumor necrosis factor receptor superfamily member 14) belongs to the tumor necrosis factor receptor superfamily. TNFRSF14 functions in signal transduction pathways that activate inflammatory and inhibitory T-cell immune response. It binds herpes simplex virus (HSV) viral envelope glycoprotein D (gD), mediating its entry into cells. A binding ELISA assay was conducted to detect the association of TNFRSF14 with TNFa. Briefly, TNFRSF14 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl TNFRSF14 were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF14 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37C. Finally, add 50 µl stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF14 and TNFa was in a dose dependent manner.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
